Curated News
By: NewsRamp Editorial Staff
September 15, 2025
LabConnect & OmniScience Launch First AI-Driven Clinical Lab Data Solution
TLDR
- LabConnect and OmniScience's AI collaboration gives clinical trial sponsors a competitive edge by accelerating decision-making and improving trial outcomes through real-time lab data insights.
- The partnership integrates LabConnect's central lab expertise with OmniScience's Vivo AI platform to unify fragmented datasets and automate oversight for streamlined clinical trial operations.
- This AI-driven solution helps bring life-changing therapies to patients faster by improving clinical trial efficiency and reducing development timelines through better data intelligence.
- LabConnect and OmniScience created the first agentic AI control tower for clinical trials, transforming static lab reports into dynamic, real-time actionable intelligence.
Impact - Why it Matters
This collaboration represents a significant advancement in clinical trial efficiency and drug development timelines. By addressing the critical problem of siloed and delayed lab data, this AI-driven solution can accelerate clinical trials, potentially bringing life-saving treatments to patients faster while reducing costs. For pharmaceutical companies and research organizations, this technology means more efficient trial oversight, reduced risks, and improved decision-making capabilities. The integration of real-time AI intelligence into clinical lab data management could fundamentally transform how clinical trials are conducted, making the entire drug development process more responsive and effective in addressing patient needs.
Summary
LabConnect, a leading global provider of central laboratory services, has announced a strategic collaboration with OmniScience, the AI company behind Vivo, the first agentic AI control tower for clinical trials. This groundbreaking partnership will deliver the industry's first AI-driven solution that enables clinical trial sponsors to gain intelligent, real-time insights from laboratory data. The collaboration combines LabConnect's expertise in central lab testing and data management with OmniScience's transformative Vivo platform, creating a powerful synergy that addresses the critical challenges of siloed, complex, and delayed clinical trial lab data.
The Vivo platform represents a significant advancement in clinical trial intelligence, functioning as an AI-native control tower that transforms how teams interact with data throughout the clinical development lifecycle. Vivo-Lab, a specialized implementation of this technology, brings sophisticated intelligence specifically to laboratory data by streamlining workflows and surfacing critical trends, anomalies, and site-level discrepancies as they occur. This enables clinical, operational, safety, and data science teams to move from reactive to proactive oversight, providing the clarity needed to act faster and more confidently in one of clinical research's most complex data streams.
According to Angela Holmes, CEO and Co-Founder of OmniScience, this partnership extends their vision of helping trial teams see and act faster by transforming lab data into real-time actionable intelligence that sponsors can trust. Wes Wheeler, CEO of LabConnect, emphasized that integrating OmniScience's transformative AI shifts lab results from static reports into dynamic, actionable intelligence, giving clinical operations teams the speed, agility, and precision needed to make smarter decisions, improve trial efficiency, and accelerate the delivery of therapies to patients. This collaboration underscores both organizations' commitment to innovation in clinical development, bringing together LabConnect's technology-driven laboratory operations with OmniScience's AI-native approach to trial intelligence.
Source Statement
This curated news summary relied on content disributed by citybiz. Read the original source here, LabConnect & OmniScience Launch First AI-Driven Clinical Lab Data Solution
